Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kineret Clear all
Terminated Phase 2 Interventional Results available

Treatment of Acute Pericarditis With Anakinra

NCT03224585
View directory record Official record
Conditions
Acute Pericarditis
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Anakinra for Inflammatory Pustular Skin Diseases

NCT01794117
View directory record Official record
Conditions
Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 110 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 24, 2026, 5:36 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Pre-emptive Anakinra for Cytokine Event Reduction

NCT06703216
View directory record Official record
Conditions
B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome, Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome
Interventions
Anakinra (Kineret®)
Drug
Lead sponsor
Kevin McNerney
Other
Eligibility
1 Year to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

NCT04359784
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma
Interventions
Anakinra, X-Ray Imaging, Positron Emission Tomography, Computed Tomography, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture, Biospecimen Collection
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Anti-Cytokine Therapy for Hemodialysis InflammatION

NCT03141983
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Anakinra, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Anakinra as a Treatment for Hydradenitis Suppurativa

NCT01516749
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
anakinra
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 24, 2026, 5:36 AM EDT
Not yet recruiting Phase 1 Interventional

Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)

NCT07600190
View directory record Official record
Conditions
Asthma (Diagnosis), Persistent Asthma, Moderate Asthma Exacerbation
Interventions
Anakinra 100 Mg/0.67 Ml Inj Syringe, Saline Placebo/0.67 Ml Inj Syringe
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Anakinra to Prevent Adverse Post-infarction Remodeling (2)

NCT01175018
View directory record Official record
Conditions
Acute Myocardial Infarction, Heart Failure
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 110 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 24, 2026, 5:36 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.

NCT04324021
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Emapalumab, Anakinra
Biological
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Saint Paul, Minnesota • Ridgewood, New Jersey • Flushing, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 24, 2026, 5:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease

NCT00069329
View directory record Official record
Conditions
Nervous System Malformations, Arthropathy, Neurogenic, Urticaria, Papilledema
Interventions
anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

NCT01624766
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Interventions
Anakinra, Denosumab, Everolimus
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

NCT02021422
View directory record Official record
Conditions
Pancreas Cancer
Interventions
anakinra, Oxaliplatin, Irinotecan, fluorouracil
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

NCT03265132
View directory record Official record
Conditions
Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
Interventions
anakinra, Placebo
Biological · Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Beverly Hills, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 24, 2026, 5:36 AM EDT
Active, not recruiting Phase 2 Interventional

Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure

NCT05177822
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Recruiting Phase 2 Interventional

Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

NCT03587701
View directory record Official record
Conditions
Autoimmune Inner Ear Disease, Meniere's Disease
Interventions
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1), Placebo injection (Period 1), Anakinra 100Mg/0.67Ml Inj Syringe (Period 2), Placebo injection (Period 2)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

NCT04148430
View directory record Official record
Conditions
B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma
Interventions
Anakinra
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional

Open-label Study of Anakinra in MPS III

NCT04018755
View directory record Official record
Conditions
Mucopolysaccharidosis III
Interventions
anakinra
Biological
Lead sponsor
Lynda E Polgreen
Other
Eligibility
4 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2

NCT03797001
View directory record Official record
Conditions
Heart Failure, Systolic, Inflammation
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Anakinra for Behcet s Disease

NCT01441076
View directory record Official record
Conditions
Autoimmune Connective Tissue Disorder, Immune System Diseases
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Early Phase 1 Interventional Results available

Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease

NCT04747847
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Atorvastatin and anakinra
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
1 Year to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease

NCT02179853
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Anakinra
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
1 Month to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease

NCT01267994
View directory record Official record
Conditions
Sensorineural Hearing Loss, Autoimmune Inner Ear Disease
Interventions
Anakinra
Drug
Lead sponsor
Andrea Vambutas
Other
Eligibility
13 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis

NCT04072822
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Anakinra and Zinc, Prednisone, Placebos
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma

NCT00635154
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
Anakinra (IL-1Ra), Dexamethasone acetate
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Sep 24, 2026, 5:36 AM EDT